Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

BofA moved to No Rating on Bluebird Bio (BLUE) after the company announced it has entered a definitive merger agreement under which Carlyle and ...

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a publicly traded company. The agreement comes after years of financial ...

Once the hottest property in biotech, gene therapy company bluebird bio has been sold for less than $500 million after a long series of setbacks.

A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...

bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales ...